GlassScriptPhysician profile
Nathan P Goldin
NPI 1033198072
$2,419.48
in general payments reported to CMS, 2019-2025
23 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $581 · 2022: $670 · 2023: $35.87 · 2024: $17.08 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $552.09 | 2022-2023 | Aquabeam Robotic System |
| Astellas Pharma US INC | $344.59 | 2019-2025 | Padcev |
| Boston Scientific Corporation | $189.60 | 2020-2024 | Solyx Sis System |
| Ferring Pharmaceuticals INC. | $152.82 | 2019-2020 | |
| Pfizer INC. | $137.32 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $134.12 | 2019-2023 | Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $133.80 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $117.61 | 2019-2020 | |
| Travere Therapeutics, INC. | $107.47 | 2019-2020 | |
| Neotract INC. | $102.87 | 2019 | |
| Janssen Biotech, INC. | $93.95 | 2019-2020 | |
| Olympus America INC. | $62.42 | 2019-2020 | |
| Acell, INC. | $57.27 | 2019-2020 | |
| Antares Pharma, INC. | $47.57 | 2019 | |
| Blue Earth Diagnostics | $38.79 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $36.68 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $32.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.56 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $20.22 | 2019 | |
| Abbott Laboratories | $17.95 | 2019 | |
| Coloplast Corp | $15.54 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$637,739.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Goldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.